Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $11.56 and last traded at $11.38, with a volume of 74269 shares trading hands. The stock had previously closed at $11.09.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.
View Our Latest Stock Analysis on FSNUY
Fresenius SE & Co. KGaA Stock Down 0.3 %
The business has a 50 day moving average of $10.64 and a two-hundred day moving average of $9.65. The stock has a market capitalization of $25.45 billion, a PE ratio of 54.24 and a beta of 0.86. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.05 and a current ratio of 1.36.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.18 EPS for the quarter. The firm had revenue of $6.01 billion during the quarter. Analysts predict that Fresenius SE & Co. KGaA will post 0.79 EPS for the current year.
About Fresenius SE & Co. KGaA
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Further Reading
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
